Esc Calculator Hcm Portal

ESC HCM Risk Calculator Formula:

\[ Probability (\%) = 1 - 0.998^{\exp(Prognostic\ Index)} \] \[ Prognostic\ Index = 0.15939858 \times MWT - 0.00294271 \times MWT^2 + 0.0259082 \times LAS + 0.00446131 \times MLVOTG + 0.4583082 \times FHSCD + 0.82639195 \times NSVT + 0.71650361 \times US - 0.01799918 \times Age \]

Maximum Wall Thickness (MWT):

Left Atrial Size (LAS):

Maximum LVOT Gradient (MLVOTG):

mm Hg

Family History of SCD (FHSCD):

Non-sustained VT (NSVT):

Unexplained Syncope (US):

Age:

years

5-Year SCD Risk Probability:

Unit Converter ▲

Unit Converter ▼

From:	To:

1. What is the ESC HCM Risk Calculator?

The ESC HCM Risk Calculator estimates the 5-year risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM) using clinical parameters. It helps guide decisions about implantable cardioverter-defibrillator (ICD) implantation.

2. How Does the Calculator Work?

The calculator uses the ESC HCM Risk-SCD formula:

Where:

MWT — Maximum wall thickness (mm)
LAS — Left atrial size (mm)
MLVOTG — Maximum LVOT gradient (mm Hg)
FHSCD — Family history of SCD (0 or 1)
NSVT — Non-sustained ventricular tachycardia (0 or 1)
US — Unexplained syncope (0 or 1)
Age — Patient age in years

3. Importance of SCD Risk Assessment

Details: Accurate risk stratification is crucial for identifying HCM patients who may benefit from ICD implantation to prevent sudden cardiac death.

4. Using the Calculator

Tips: Enter all required parameters. MWT, LAS, and MLVOTG should be from recent echocardiographic measurements. Binary variables (FHSCD, NSVT, US) should be coded as 1 (present) or 0 (absent).

5. Frequently Asked Questions (FAQ)

Q1: What is considered a high-risk score?
A: Generally, ≥6% 5-year risk is considered high enough to warrant ICD consideration, but clinical judgment is always required.

Q2: How often should risk be reassessed?
A: Risk should be reassessed every 1-2 years or when new clinical events occur.

Q3: What are the limitations of this calculator?
A: It may underestimate risk in patients with certain high-risk features like extreme hypertrophy (>30mm) or recent sustained VT.

Q4: Can this be used for pediatric patients?
A: The calculator was validated in patients ≥16 years old and should be used with caution in younger patients.

Q5: How should borderline results be interpreted?
A: For intermediate risk scores (4-6%), additional risk modifiers and shared decision-making are particularly important.